Price movement over the last 24 hours
AdaptHealth Corp vs Honeywell International Inc — how do they compare? AdaptHealth Corp trades at $10.1 (market cap $1.38B), while Honeywell International Inc trades at $222.01 (market cap $71.30B). The key difference: Honeywell International Inc is far larger — about 51.7× AdaptHealth Corp's market cap, and Honeywell International Inc pays a 4.23% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | HON | |
|---|---|---|
Market Cap | $1.38B | $71.30B |
Sector | Health | Industrials |
52-Week High | $13.38 | $248.04 |
52-Week Low | $8.68 | $188.14 |
Enterprise Value | $3.33B | $95.65B |
Dividend Yield | — | 4.23% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Honeywell Technologies (HON) trades at $225.05, down 2.09% today, following the completion of its aerospace spinoff on June 29, 2026. The stock shows strong fundamentals with a P/E of 18.46 and consistent earnings beats in recent quarters. Technical indicators suggest a bullish trend with support at $225 and resistance at $234. The company maintains solid profitability with 10.89% net margins and 26.41% ROE, though revenue declined slightly to $37.44B in 2025.
The outlook remains positive with 64% analyst buy ratings and a $402.40 consensus price target, representing 79% upside potential. Key risks include integration challenges from recent spinoffs and rising debt-to-asset ratio (46.65% in 2025). The company's focus on high-growth automation segments and ESG alignment provides long-term growth catalysts, though near-term volatility may persist during the post-spinoff transition period.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →